Efficacy and safety of platelet additive solution-E stored platelet concentrates

Introduction: In 2018, platelet (PLT) additive solution-E (PAS-E) was introduced. The implementation of PAS-E was expected to diminish the number of allergic reactions in recipients following a PLT transfusion. Here, we evaluated the efficacy and safety of transfusions with PLTs stored in PAS-E.Study Design and Methods: After implementation of PAS-E, data were collected from 2 cohorts of patients with hematological disorders as well as oncology patients, receiving PLTs in PAS-E. A similar patient group in a recent RCT, receiving PLTs in plasma, was used as a historical control group for both cohorts. Endpoints were corrected count increments (CCIs), bleeding scores (only reported in cohort 1), and the incidence of adverse reactions.Results: In cohort 1, the mean 1-h CCI was 14.3 +/- 6.9, and the 24-h CCI was 8.7 +/- 5.6. In cohort 2, the 1-h CCI was 11.6 +/- 7.8 and the 24-h CCI was 7.0 +/- 6.1. In the control group, the 1-h CCI was 15.4 +/- 5.5 and 24-h CCI 8.7 +/- 4.8. Bleeding complications of WHO grade >= 2 occurred in 40% of patients in cohort 1 compared to 44% in plasma PCs. The incidence of adverse reactions was 1.2% in the two PAS-E cohorts, compared to 3.0% in plasma PCs. National hemovigilance data showed a significant reduction in allergic reactions with PAS-E PC transfusions as compared to plasma PCs with an odds ratio of 0.46 (CI 95% 0.37-0.58).Conclusion: The CCIs of PLTs in PAS-E were decreased compared to plasma PCs, but clinically acceptable. Allergic transfusion reactions were decreased in PAS-E PCs compared to plasma PCs.